KR100519904B1 - 에리트로포이에틴 및 개질된 헤모글로빈을 함유하는 약학복합제제 - Google Patents

에리트로포이에틴 및 개질된 헤모글로빈을 함유하는 약학복합제제 Download PDF

Info

Publication number
KR100519904B1
KR100519904B1 KR10-1999-7012111A KR19997012111A KR100519904B1 KR 100519904 B1 KR100519904 B1 KR 100519904B1 KR 19997012111 A KR19997012111 A KR 19997012111A KR 100519904 B1 KR100519904 B1 KR 100519904B1
Authority
KR
South Korea
Prior art keywords
erythropoietin
hemoglobin
formulation
modified hemoglobin
epo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1999-7012111A
Other languages
English (en)
Korean (ko)
Other versions
KR20010014075A (ko
Inventor
레만파울
타운미햐엘-하롤트
포이어슈타인위르겐
Original Assignee
로셰 디아그노스틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로셰 디아그노스틱스 게엠베하 filed Critical 로셰 디아그노스틱스 게엠베하
Publication of KR20010014075A publication Critical patent/KR20010014075A/ko
Application granted granted Critical
Publication of KR100519904B1 publication Critical patent/KR100519904B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-1999-7012111A 1997-06-21 1998-06-03 에리트로포이에틴 및 개질된 헤모글로빈을 함유하는 약학복합제제 Expired - Fee Related KR100519904B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97110168A EP0885613A1 (de) 1997-06-21 1997-06-21 Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
EP97110168.8 1997-06-21
PCT/EP1998/003299 WO1998058660A1 (de) 1997-06-21 1998-06-03 Pharmazeutische kombinationspräparate enthaltend erythropoietin und modifizierte hämoglobine

Publications (2)

Publication Number Publication Date
KR20010014075A KR20010014075A (ko) 2001-02-26
KR100519904B1 true KR100519904B1 (ko) 2005-10-10

Family

ID=8226937

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7012111A Expired - Fee Related KR100519904B1 (ko) 1997-06-21 1998-06-03 에리트로포이에틴 및 개질된 헤모글로빈을 함유하는 약학복합제제

Country Status (15)

Country Link
US (3) US6440932B1 (https=)
EP (2) EP0885613A1 (https=)
JP (3) JP2002504913A (https=)
KR (1) KR100519904B1 (https=)
CN (1) CN1185010C (https=)
AT (1) ATE272405T1 (https=)
AU (1) AU743475B2 (https=)
BR (1) BR9810267A (https=)
CA (1) CA2294448C (https=)
DE (1) DE59811768D1 (https=)
DK (1) DK0996462T3 (https=)
ES (1) ES2226151T3 (https=)
PT (1) PT996462E (https=)
TR (1) TR199903192T2 (https=)
WO (1) WO1998058660A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT977582E (pt) * 1997-03-18 2002-12-31 Roche Diagnostics Gmbh Preparacoes farmaceuticas associadas contendo eritropoietina e preparacoes de ferro
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
PL219131B1 (pl) * 2000-05-15 2015-03-31 Hoffmann La Roche Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie
CA2431964C (en) 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
DE10215315A1 (de) * 2002-04-05 2003-11-20 Aventis Behring Gmbh Intellect Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
BRPI0414887A (pt) * 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
RU2273485C2 (ru) * 2004-05-19 2006-04-10 Виктор Николаевич Алейников Железосодержащий препарат "феррал"
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
PL2054074T3 (pl) 2006-08-04 2015-03-31 Prolong Pharmaceuticals Llc Zmodyfikowana erytropoetyna
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
PT3380487T (pt) 2015-11-23 2020-10-29 Bristol Myers Squibb Co Sistemas de aditivos para utilização na peguilação de proteínas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024213A1 (en) * 1994-03-08 1995-09-14 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
NO881507D0 (no) * 1987-04-10 1988-04-07 Ortho Pharma Corp Fremgangsmaate for forhoeyning av hematokritnivaaet til et normalt pattedyr.
JPH03112934A (ja) * 1989-09-27 1991-05-14 Mitsubishi Kasei Corp 圧縮成型可能な粉体組成物
CA2180529A1 (en) * 1994-11-17 1996-05-30 John Blue Hemoglobin therapy in hemodialysis
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
EP0939644B1 (en) * 1996-08-27 2004-01-14 Hemosol Inc. Enhanced stimulation of erythropoiesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024213A1 (en) * 1994-03-08 1995-09-14 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin

Also Published As

Publication number Publication date
JP5785008B2 (ja) 2015-09-24
TR199903192T2 (xx) 2000-05-22
EP0996462B1 (de) 2004-08-04
US6440932B1 (en) 2002-08-27
CN1185010C (zh) 2005-01-19
CN1261282A (zh) 2000-07-26
AU8109898A (en) 1999-01-04
AU743475B2 (en) 2002-01-24
JP2007246530A (ja) 2007-09-27
CA2294448C (en) 2007-12-11
ES2226151T3 (es) 2005-03-16
EP0996462A1 (de) 2000-05-03
DK0996462T3 (da) 2004-11-29
US20020160956A1 (en) 2002-10-31
WO1998058660A1 (de) 1998-12-30
KR20010014075A (ko) 2001-02-26
CA2294448A1 (en) 1998-12-30
PT996462E (pt) 2004-12-31
DE59811768D1 (de) 2004-09-09
EP0885613A1 (de) 1998-12-23
JP2011246474A (ja) 2011-12-08
US20050197281A1 (en) 2005-09-08
BR9810267A (pt) 2000-09-12
ATE272405T1 (de) 2004-08-15
JP2002504913A (ja) 2002-02-12

Similar Documents

Publication Publication Date Title
JP5785008B2 (ja) エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤
ES2218851T3 (es) Uso de la eritropoyetina y de preparados de hierro para la fabricacion de preparados farmaceuticos de combinacion para el tratamiento de enfermedades reumaticas.
US20110195046A1 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US6333306B1 (en) Pharmaceutical combination preparations containing erythropoietin and iron preparations
CA2491682A1 (en) Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine
AU2002256133A1 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
ES2326501T3 (es) Uso de eritropoyetina para el tratamiento de hemocromatosis primaria.
Fishbane et al. Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis
Hudson et al. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease
JPH03190823A (ja) エリスロポエチン皮下又は筋肉投与剤
MXPA99011664A (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
JPH0296535A (ja) 骨髄機能障害性貧血治療剤
AU2003249991B8 (en) Liquid formulations with a high concentration of human growth hormone (hGH) comprising glycine
EP1930023A2 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
KR20000076259A (ko) 에리트로포이에틴과 철 제제를 포함하는 약학 조합제제
MXPA99011446A (en) Stable insulin formulations
CN1248920A (zh) 含促红细胞生成素和铁制剂的药物联合制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20081001

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20081001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000